Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Drone Video of the Year is stunning – you've not seen Namibia like this - 2Giant ‘toothed’ birds flew over Antarctica 40 million to 50 million years ago
- 3Dominating the Remote Work Way of life: Individual Systems
- 410 Moving Design Frill for Summer 2023
- 5Step by step instructions to Deal with Your Time While Chasing after an Internet based Degree
- A Gustav Klimt painting is now the most expensive piece of modern art sold at auction. The fascinating history behind the $236 million 'Portrait of Elisabeth Lederer.'
- Partner of crime boss Steven Lyons arrested in Dubai
- Red Sea arena: Yemen’s Houthis open fourth front in Iran war, with global implications
- Deadly Switzerland ski resort fire was likely started by sparklers attached to champagne bottles, officials say
- The newest 'Project Hail Mary' trailer shows Ryan Gosling befriending an alien in Phil Lord and Chris Miller's space epic
- Nurturing Hacks: Astuteness from Experienced Mothers and Fathers
- The 10 Most Significant Games in History
- Make your choice for a definitive Christmas place to get-away!
- NASA probe captures stunning photos of Earth and moon on the way to infamous asteroid Apophis
